Skip to Main content Skip to Navigation
Journal articles

Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases

Abstract : Abstract Background In the INBUILD trial in patients with chronic fibrosing interstitial lung diseases (ILDs) and a progressive phenotype, nintedanib reduced the rate of ILD progression with adverse events that were manageable for most patients. We investigated the potential impact of immunomodulatory therapies on the efficacy and safety of nintedanib. Methods Subjects with fibrosing ILDs other than idiopathic pulmonary fibrosis, who had shown progression of ILD within the prior 24 months despite management in clinical practice, were randomized to receive nintedanib or placebo. Certain immunomodulatory therapies were restricted for the first 6 months. We analyzed post-hoc the rate of decline in forced vital capacity (FVC) over 52 weeks in subgroups by glucocorticoid use at baseline and in analyses excluding subjects or FVC measurements taken after initiation of restricted immunomodulatory or antifibrotic therapies. Results Of 663 subjects, 361 (54.4%) were taking glucocorticoids at baseline (353 at a dose of ≤ 20 mg/day). In the placebo group, the adjusted rate of decline in FVC (mL/year) over 52 weeks was numerically greater in subjects taking than not taking glucocorticoids at baseline (− 206.4 [SE 20.2] vs − 165.8 [21.9]). The difference between the nintedanib and placebo groups was 133.3 (95% CI 76.6, 190.0) mL/year in subjects taking glucocorticoids at baseline and 76.1 (15.0, 137.2) mL/year in subjects who were not (interaction P = 0.18). The effect of nintedanib on reducing the rate of FVC decline in analyses excluding subjects or measurements taken after initiation of restricted immunomodulatory or antifibrotic therapies was similar to the primary analysis. The adverse event profile of nintedanib was similar between subjects who did and did not use prohibited or restricted therapies at baseline or during treatment with trial drug. Conclusions In patients with progressive fibrosing ILDs, the effect of nintedanib on reducing FVC decline was not influenced by the use of immunomodulatory therapies. Nintedanib can be used in combination with immunomodulatory therapies in patients with progressive fibrosing ILDs. Trial registration ClinicalTrials.gov, NCT02999178. Registered 21 December 2016, https://clinicaltrials.gov/ct2/show/NCT02999178
Complete list of metadata

https://hal.inrae.fr/hal-03299774
Contributor : Sabine Rossi <>
Submitted on : Monday, July 26, 2021 - 4:40:55 PM
Last modification on : Tuesday, July 27, 2021 - 3:37:39 AM

Licence


Distributed under a Creative Commons Attribution 4.0 International License

Links full text

Identifiers

Collections

Citation

Vincent Cottin, Luca Richeldi, Ivan Rosas, Maria Otaola, Jin Woo Song, et al.. Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases. Respiratory Research, BioMed Central, 2021, 22 (1), ⟨10.1186/s12931-021-01668-1⟩. ⟨hal-03299774⟩

Share

Metrics

Record views

5